Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype-Reference-Cited by-同舟云学术

Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype

Published:2018-01 Issue:1 Volume:20 Page:110-122
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Pellegrini Cristina^ORCID,Di Nardo Lucia^ORCID,Cipolloni Gianluca,Martorelli Claudia,De Padova Marina,Antonini Ambra,Maturo Maria Giovanna,Del Regno Laura,Strafella Sara,Micantonio Tamara,Leocata Pietro,Peris Ketty,Fargnoli Maria Concetta

Funder

Italian Ministry of the University and Scientific Research

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference54 articles.

1. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics;Lo;Science,2014

2. Emerging trends in the epidemiology of melanoma;Nikolaou;Br J Dermatol,2014

3. Increased risk of second primary cancers after a diagnosis of melanoma;Bradford;Arch Dermatol,2010

4. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas;Murali;Ann Surg Oncol,2012

5. Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study;Savoia;J Eur Acad Dermatol Venereol,2012

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques;Current Oncology;2024-02-05

2. LncRNAs and related molecular basis in malignant pleural mesothelioma: Challenges and potential;Critical Reviews in Oncology/Hematology;2023-06

3. TERT Promoter Mutational Analysis as an Ancillary Diagnostic Tool for Diagnostically Challenging Melanocytic Neoplasms;The American Journal of Dermatopathology;2023-02-17

4. Liquid biopsies in primary and secondary bone cancers;Cancer Drug Resistance;2022

5. Epigenetic modification and BRAF gene mutation in thyroid carcinoma;Cancer Cell International;2021-12